| DC49518 |
Antiviral agent 15 |
Antiviral agent 15 (Compound 15f) is a Clofazimine derivative with antiviral effects. Antiviral agent 15 inhibits both rabies virus and pseudo-typed SARS-CoV-2 with EC50 values of 1.45 μM and 14.6 μM, respectively. |
|
| DC49519 |
αGalCer-RBD |
αGalCer-RBD is a self-adjuvanting lipoprotein conjugate. αGalCer-RBD induces potent immunity against SARS-CoV-2 and its variants of concern. αGalCer-RBD conjugate induces RBD-specific, cytokine-producing T cell development. αGalCer-RBD has great potential to be an effective COVID-19 vaccine candidate. α-Galactosylceramide (αGalCer) is a potent invariant natural killer T cell (iNKT) agonist. RBD: receptor-binding domain |
|
| DC80018 |
VV116
Featured
|
VV116, also known as JT001, is an oral drug candidate of nucleoside analog against SARS-CoV-2. VV116 is a deuterated, tri-isobutyrate ester prodrug of the RDV parent nucleoside, and is rapidly metabolized into the parent nucleoside (116-N1) in the body. 116-N1 is intracellularly converted to the nucleoside triphosphate active form, which would interfere with the function of RNA-dependent RNA polymerase of SARS-CoV-2, thus exerting antiviral effects (Fig. 1). VV116 showed potent activity against a panel of SARS-CoV-2 variants (alpha, beta, delta, and omicron) and excellent therapeutic efficacy in the mice model. |
|
| DC71280 |
Coronastat |
Coronastat is a potent inhibitor of the SARS-CoV-2 3CL protease. The SARS-CoV-2 3CL protease is a critical drug target for small molecule COVID-19, given its likely druggability and essentiality in the viral maturation and replication cycle. |
|
| DC71281 |
FWM-1 |
FWM-1 is a potent SARS-COV-2 NSP13 helicase enzyme inhibitor with binding free energy equals -328.6 kcal/mol. FWM-1 effectively disrupts the binding of ATP to the SARS-COV2 helicase enzyme. |
|
| DC71282 |
Fmoc-leucine-15N |
Fmoc-leucine-15N is a 15N-labeled and 13C-labled EIDD-1931. EIDD-1931 (Beta-d-N4-hydroxycytidine; NHC) is a novel nucleoside analog and behaves as a potent anti-virus agent. EIDD-1931 effectively inhibits the replication activity of venezuelan equine ence |
|
| DC71283 |
FWM-4 |
FWM-4 is a potent SARS-COV-2 NSP13 helicase enzyme inhibitor. |
|
| DC71284 |
FWM-5 |
FWM-5 is a potent NSP13 helicase inhibitor. SARS-COV-2 NSP13 helicase enzyme plays crucial role in the virus life cycle. FWM-5 has the potential for the research of infection diseases. |
|
| DC71716 |
Obeldesivir (GS-5245, ATV006)
Featured
|
ATV006 is a potent, orally active antiviral agent and ester prodrugs of GS-441524. ATV006 inhibits the replication of SARS-CoV-2 and its variants. ATV006 can be used for SARS-CoV-2 research. |
|
| DC71717 |
MI-1851 |
MI-1851 is a potent furin inhibitor. MI-1851 prevents the proteolytic processing of the S protein of SARS-CoV-2 by endogenous flavoprotease in HEK293 cells. MI-185 has antiviral activity. |
|
| DC71718 |
PLP_Snyder530 |
PLP_Snyder530 is a potent papain-like protease (PLpro) inhibitor. PLP_Snyder530 induces conformational changes in SARS-COV-2 papain-like protease, inhibiting SARS-CoV-2 replication. PLP_Snyder530 can be used for SARS-CoV-2 research. |
|
| DC71719 |
XR8-89 |
XR8-89 is a potent papain-like protease (PLpro) inhibitor. XR8-89 induces conformational changes in SARS-COV-2 papain-like protease, inhibiting SARS-CoV-2 replication. XR8-89 can be used for SARS-CoV-2 research. |
|
| DC71720 |
ZINC000104379474 |
ZINC000104379474 is a compound that targets SARS-CoV-2 endoribonuclease. |
|
| DC71900 |
MM3122
Featured
|
MM-3122 is a selective inhibitor of host cell serine protease TMPRSS2 (transmembrane protease serine 2) with IC50 of 0.34 nM against recombinant full-length TMPRSS2 protein. |
|
| DC72013 |
MMT5-14 |
MMT5-14 is a remdesivir analogue with a higher antiviral activity in four variants of SARS-CoV-2 than Remdesivir. MMT5-14 inhibits SARS-CoV-2, α, β, γ and δ variants with EC50s of 0.4, 2.5, 15.9, 1.7 and 5.6 μM, respectively. MMT5-14 can be used for the research of COVID-19.
|
|
| DC72297 |
Bofutrelvir |
Bofutrelvir (FB2001) is a SARS-CoV-2 main protease Mpro inhibitor with an IC50 value of 53 nM and an EC50 value of 0.53 μM. Bofutrelvir exhibits potent antiviral efficacy against several current SARS-CoV-2 variants with EC50 values of 0.26-0.42 μM. Bofutrelvir has an additive antiviral effect when combined with Remdesivir. |
|
| DC72580 |
Isomitomycin A |
Isomitomycin A is a potential inhibitor against SARS-CoV-2. Isomitomycin A targets to the hACE2 binding site of the modelled surface glycoprotein of SARS-CoV-2. Isomitomycin A can be used in studies of COVID-19. |
|
| DC72831 |
RAY1216 |
RAY1216 is an orally active SARS-CoV-2 main protease slow-tight inhibitor with a Ki of 8.6 nM. |
|
| DC73032 |
(S)-chlorcyclizine |
(S)-chlorcyclizine ((S)-CCZ) is an approved antihistamine drug that is related to dichlorcyclizine (DCCZ), inhibits SARS-CoV and SARS-CoV-2 S-mediated infection in MA104 cells with EC50 of 6.91 and 4.09 uM. |
|
| DC73033 |
AB-00011778 |
AB-00011778 is a small molecule inhibitor of SARS-CoV-2 entry and the Spike/ACE2 interaction, inhibits viral replication with EC50 of 250 nM in A549-ACE2 cells, AB-00011778 is equally effective in impairing the S/ACE2 association in the different mutants. |
|
| DC73034 |
AC1115 |
AC1115 is a potent, selective, next-generation antiviral targeting SARS-CoV-2 Mpro and host lysosomal cysteine protease cathepsin L (CTSL) with high antiviral activity, AC1115 is the active form of Olgotrelvir. |
|
| DC73035 |
Acriflavine |
Acriflavine (Acriflavin) is a topical antiseptic that found to be a potent papain-like protease (PLpro) inhibitor, inhibits SARS-CoV-2 and other betacoronaviruses. |
|
| DC73036 |
ALG-097111 |
ALG-097111 is a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease (3CLpro) with IC50 of 7 nM, without effect against human cathepsin L (IC50>10 uM). |
|
| DC73037 |
Cyanorona-20 |
Cyanorona-20 is a potent and specific SARS-CoV-2 inhibitor with very high selectivity (209- and 45-fold more potent than favipiravir and remdesivir, respectively), effectively binds to and inhibits the SARS-CoV-2 RdRp. |
|
| DC73038 |
D-4-77 |
D-4-77 is a potent, covalent peptidyl inhibitor of SARS-CoV-2 main protease (Mpro) with IC50 of 0.95 uM and antiviral EC50 of 0.49 uM. |
|
| DC73039 |
Difluorobenztropine |
Difluorobenztropine (AHN 1-055) is a direct-acting SARS-CoV-2 entry inhibitor that targets the SARS-CoV-2 spike fusion peptide domain. |
|
| DC73040 |
DMGA |
DMGA is an allosteric and covalent inhibitor of SARS-CoV-2 papain-like protease (SARS-CoV-2 PLpro) with IC50 of 9.4 uM, covalently binds with C270 of the SARS-CoV-2 PLpro. |
|
| DC73041 |
DS0464 |
DS0464 is a selective, bisubstrate competitive inhibitor SARS-CoV-2 nonstructural protein 14 (nsp14) with IC50 of 1.1 uM, also selective against 28 out of 33 RNA, DNA, and protein MTases. |
|
| DC73043 |
EIDD-2801 |
EIDD-2801 (MK-4482, Molnupiravir) is a highly potent ribonucleoside analog, and prodrug of EIDD-1931, exhibits broad-spectrum antiviral inhibitor of multiple RNA viruses including SARS-CoV-2. |
|
| DC73044 |
GC-14 |
GC-14 is a potent, selective and non-covalent non-peptide SARS-CoV-2 main protease (Mpro) inhibitor with IC50 of 0.4 uM, displays excellent selectivity over cathepsins B, F, K, L, and caspase 3 (IC50>50 uM). |
|
